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Advanced glycation end products (AGEs) are the products of a series of nonenzymatic modiﬁcations of proteins by reducing
sugars. AGEs play a pivotal role in development of diabetic complications and atherosclerosis. Accumulation of AGEs in a
vessel wall may contribute to the development of vascular lesions. Although AGEs have a diverse range of bioactivities, the
clearance process of AGEs from the extracellular space, including the incorporation of AGEs into speciﬁc cells, subcellular
localization, and the fate of AGEs, remains unclear. In the present study, we examined the kinetics of the uptake of AGEs by
mouse macrophage J774.1 cells in vitro and characterized the process. We demonstrated that AGEs bound to the surface of the
cells and were also incorporated into the cytoplasm. The temperature- and time-dependent uptake of AGEs was saturable with
AGE concentration and was inhibited by cytochalasin D but not chlorpromazine. We also observed the granule-like
appearance of AGE immunoreactivity in subcellular localizations in macrophages. Higher concentrations of AGEs induced
intracellular ROS and 4-HNE, which were associated with activation of the NF-κB pathway and caspase-3. These results
suggest that incorporation of AGEs occurred actively by endocytosis in macrophages, leading to apoptosis of these cells
through NF-κB activation.
1. Introduction
AGEs (advanced glycation end products) are the products of
a series of nonenzymatic modiﬁcations of proteins by reduc-
ing sugars such as ribose, glucose, or glucose-6-phosphate
that are related to processes involved in some progressive
vascular aging diseases. Long-term incubation of proteins
with glucose leads to advance glycation end products (AGEs)
through the formation of early products such as Schiﬀ bases
and Amadori products. This process also exists in our body
because every day we ingest such compounds in our diet
[1]. In a healthy body, homeostasis controls these processes
to maintain steady state or dynamic stability. However, in
diabetic patients, high levels of blood glucose induce contin-
uous irreversible glycation and oxidation of proteins and
lipids, which lead to the formation of AGEs [2].
There is a plethora of evidence linking inﬂammation to
the pathogenesis of vascular complications in diabetes. The
formation of AGEs in arterial wall proteins such as the
extracellular matrix may be responsible for accelerated ath-
erosclerosis and microvascular disorders. One of the ways
AGEs exert their cellular eﬀects is by binding to receptors
on the cell surface, such as the receptor for AGE (RAGE),
lactoferrin-like polypeptide (LF-L), and scavenger receptor-
A on macrophages [3–5]. Recent studies have revealed that
the interaction of AGEs with RAGE receptors evokes oxida-
tive and proapoptotic reactions in various types of cells and
is thus involved in the pathogenesis of vascular complications
in diabetes [6]. Apart from the receptor pathway, the
accumulation of AGEs may be accompanied by protein
cross-linking and cell damage. It has been reported that
administration of an AGE aptamer signiﬁcantly suppressed
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inﬂammatory cytokine expression in the kidneys of DMmice
and prevented renal dysfunction by decreasing plasma levels
of urea nitrogen and creatinine [7]. Although it is well known
that AGEs are present in atherosclerotic plaques, especially in
patients with diabetes, and that AGEs appear to be involved
in macrophage foam cell formation, the precise mechanisms
of their roles in these contexts are poorly understood [8].
Thus, it is important to understand the fate of endogenously
produced AGE proteins and how they are eliminated from
circulation in the homeostatic condition. There is evidence
that macrophages play a pivotal role in eliminating AGEs
and maintaining homeostasis by scavenger-receptor-
mediated endocytosis in hepatic sinusoidal Kupﬀer and
endothelial cells [9]. However, we still do not know the exact
mechanism by which macrophages clear AGEs and the cell
fate of macrophages after exposure to AGEs.
In the present study, our observations focused on the
incorporation of AGEs in macrophages and the subcellular
localization of AGEs. The results revealed that the incor-
poration of AGEs and the subsequent fate of AGEs in
macrophages are dynamic processes and that caspase-3-
dependent cell death is essential to the pathophysiological
nature of these processes.
2. Materials and Methods
2.1. Reagents. AGEs were produced at our laboratory using
BSA from Sigma (St. Louis, MO) as substrate proteins. The
antibodies against AGEs were raised according the method
of Morioka et al. [10] as mentioned below. The following
reagents were purchased from commercial sources: RPMI-
1640 medium (Sigma); penicillin-streptomycin solution
(Sigma); 200mM L-glutamine (Invitrogen, Carlsbad, CA);
fetal bovine serum 16000 (Invitrogen); PBS, TBS and
formaldehyde solution (Sigma); 10mM Tris-buﬀered saline
and formaldehyde solution (Katayama Chemical Indus-
tries, Osaka, Japan); and Triton X-100 (Nacalai Tesque,
Kyoto, Japan). Normal goat serum, normal rabbit IgG,
AlexaFluor 488-labeled goat anti-rabbit IgG (H+L), and
AlexaFluor 555 goat anti-mouse IgG (H+L) were obtained
from Abcam (Cambridge, UK); rabbit-caspase-3 antibody
from Cell Signaling (Danvers, MA); anti-NF-κB p65 anti-
body (Rb pAb; 16502) from Abcam; antiphosphatidylserine
antibody from Upstate Biotechnology (Lake Placid, NY);
goat anti-rabbit IgG (HRP) and DAPI from Life Technology
(Carlsbad, CA); and West Dura extended duration substrate,
2′,7′-dichlorodihydroﬂuorescein diacetate (H2DCF-DA),
and nuclear and cytoplasmic extraction (NE-PER) reagents
from Thermo Scientiﬁc (Waltham, MA).
2.2. Synthesis of AGEs. BSA was incubated under sterile
conditions with 0.2M glyceraldehyde (Sigma-Aldrich) and
glycol aldehyde (Sigma-Aldrich), respectively, in 0.2M phos-
phate buﬀer for 7 days (pH 7.4 at 37°C). AGE-2 and AGE-3
correspond to Glycer-AGEs and Glycol-AGEs, respectively.
Each of the AGEs-BSA was dialyzed at 4°C to remove free
aldehyde. The degree of glycation on BSA (AGE-BSA ﬂuo-
rescence) was measured by spectroﬂuorometric detection at
excitation of 370nm and emission of 440nm.
2.3. Anti-AGE-Speciﬁc Polyclonal Antibody. Antibodies were
produced from Japanese white rabbits. Rabbits were immu-
nized with 5ml AGEs-BSA emulsiﬁed with the same volume
of Freund’s complete adjuvant (Wako). The rabbits received
ﬁrst booster injection after three weeks, followed by two addi-
tional booster injections every week with emulsiﬁed Freund’s
incomplete adjuvant. After the whole blood was collected
from the immunized rabbits under anesthesia, the antisera
titers were determined by immunoblot analysis. Immuno-
globulin fractions was puriﬁed using MEP HyperCel (Pall,
Port Washington, NY, USA). Anti-AGE-speciﬁc antibodies
were puriﬁed by using each of AGEs-BSA immobilized on
Sepharose beads (GE Healthcare, Buckinghamshire, UK).
2.4. Cell Preparation. The murine cell line J774.1 (BALB/c)
was purchased from JCRB Cell Bank (Osaka, Japan). Cells
were incubated at 37°C in RPMI1640 medium (contain-
ing 10% FBS, 200mM glutamine and 1% penicillin-
streptomycin solution) in a 5% CO2 humidiﬁed atmosphere
and passaged every 3-4 days. After three passages, the cell
suspension (106 cells/ml) was divided into 0.1ml aliquots
that were incubated for 2 hrs in wells of a 96-well plate; then
the medium with FBS was removed. Cells with a new
medium without FBS were coincubated in the presence or
absence of AGEs (Falcon 353219 microtiter plate).
2.5. Immunoﬂuorescence Detection of AGEs after
Incorporation into J774.1 Cells. After incubation in the
presence or absence of AGEs for 2 hrs, cells (105 cells/well)
were ﬁxed with 10% formaldehyde for 20min and then
washed three times with PBS for 5min each time. When
the cell membranes were disrupted, 10min incubation with
0.2% Triton X-100/TBS was performed; then, 3% normal
goat serum (0.1% T-TBS) was used as a blocking agent for
immunoﬂuorescence detection. After 30min, the samples
were incubated with rabbit polyclonal anti-AGE-2 or anti-
AGE-3, or normal rabbit IgG (1 : 250) at room temperature
for 1 hr. After three washes in T-TBS, cells were incubated
for 1 hr with a secondary antibody (AlexaFlour 488-labeled
goat anti-rabbit IgG) at room temperature. The ﬂuorescence
intensity was determined by FlexStation 3 mutimode micro-
plate reader within one hour after washing cells with 0.1% T-
TBS three times. Before observing the cells, we changed the
platemedium(0.1%T-TBS) intoTBS(non-TritonX) solution.
The cells were observed under ﬂuorescent microscopy (Bio-
zero BZ8000; Keyence, Osaka, Japan). The 3D pictures were
takenbyconfocalmicroscopy (LSM780Zesis Jena,Germany).
2.6. Intracellular ROS Assay. Intracellular ROS activity was
detected by 2′,7′-dichlorodihydroﬂuorescein diacetate
(H2DCF-DA). An H2DCF-DA ﬂuorescent probe is com-
monly employed and reacts with several ROS, including
hydrogen peroxide, hydroxyl radicals, and peroxynitrite.
We detected intracellular ROS after exposure of J774.1 cells
to AGEs. The cells were plated at a concentration of 106
cells/ml (1× 105 cells per well) into a 96-well plate. After
stimulation by AGEs for 24 hrs, the cells were washed by
PBS three times and loaded with 5μM H2DCFDA at room
temperature in the dark for 15min. The ﬂuorescence was
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measured with excitation at 485nm and emission at 510nm.
Fluorescence images of cells were taken by a BZ-X700
(Keyence, Osaka, Japan) ﬂuorescence microscope.
2.7. Western Blot Analysis of Proteins. To analyze the cellular
proteins, 6-well plates were used, with each well containing
1ml of cell suspension (5× 106 cells/ml). AGE-2 and AGE-
3 were diluted with PBS to give the ﬁnal concentration of
20μg/ml or 100μg/ml. Cells were preincubated at 37°C for
1 hr, then stimulated with AGEs for 0, 1, 2, 4, 6, 8, 12, and
24 hrs. After obtaining cell pellets by centrifugation, cells
were treated with SDS-PAGE sample buﬀer (10% SDS, 1%
β-mercaptoethanol, 2% Tris-HCl (pH6.8), 20% glycerin,
0.01% bromophenol blue, H2O). Proteins were separated by
SDS-PAGE and electrophoretically blotted onto nitrocellu-
lose membranes (Bio-Rad, Hercules, CA). After blocking
with 1% BSA in PBS, the membranes were incubated with
rabbit primary antibodies at 4°C overnight. After the incu-
bation with goat anti-rabbit IgG (HRP), the protein bands
were visualized by the luminal-based enhanced chemilumi-
nescence (ECL) HRP substrate method (Thermo Fisher
Scientiﬁc Inc.). An Image Quant LAS4000 system was
used for detection.
2.8. Phosphatidylserine Staining. After stimulation with
100μl AGE-2 or AGE-3 for 12 hrs, J774.1 cells were ﬁxed
with 10% formaldehyde for 20min and then washed three
times for 5min each in PBS. The buﬀer 0.2% Triton X-100/
TBS could not be used because of the disruption of cell mem-
brane. Blocking with 3% normal goat serum (0.1% T-TBS)
for 30min was performed before immunostaining. In these
experiments, double immunostaining of cells with mouse
anti-phosphatidylserine was performed. Alexa Fluor 555
goat anti-mouse IgG (H+L) and Alexa Fluor 488-labeled
goat anti-rabbit IgG were used as secondary antibodies
for double staining.
2.9. Statistical Analysis. Statistical signiﬁcance was evaluated
by ANOVA followed by Dunnett’s test for multiple compar-
isons, or by Student’s t-test for comparisons between two
groups. P values less than 0.05 were considered signiﬁcant.
3. Results
3.1. Uptake of AGEs in J774.1 Macrophages. Figure 1 shows
the temperature-dependent uptake of AGE-2 and AGE-3
into J774.1 macrophages at 2 hrs after the start of incubation.
At 4°C, low levels of AGE binding were observed on the cell
surface, irrespective of the presence or absence of Triton X-
100 during the detection of antigens by the primary antibody.
At 37°C, cell membrane-associated staining was apparent in
the absence of Triton X-100, especially in the case of AGE-
3, whereas the immunoreactivities for both AGE-2 and
AGE-3 were enhanced in the cell-membrane-associated area
and the intracellular compartment in the presence of Triton
X-100. Thus, the ﬂuorescence intensities of AGEs in the pres-
ence of Triton X-100 were signiﬁcantly higher than those in
the absence of Triton X-100 at 37°C. The quantitative deter-
minations are summarized in Figure 1(c).
3.2. Time-Course and Concentration Dependency of the
Intracellular Uptake of AGE-2 and AGE-3 and Their
Subcellular Localization in Macrophages. We determined
time-course changes in the uptake of AGE-2 and AGE-3 in
macrophages. The uptake of AGE-2 and AGE-3 was time-
dependent and the ﬂuorescence intensities of AGE-2 and
AGE-3 increased up to 30min. Although the ﬂuorescence
intensity of the cells was relatively constant thereafter, the
distribution pattern of immunoreactivities was changed
time-dependently and signiﬁcantly with highly positive spots
for both AGE-2 and AGE-3 (Figure 2(a)). Figure 2(b) shows
the concentration dependency of the uptake of AGE-2 and
AGE-3 in macrophages at 30min. The concentration-
dependency curves for AGE-2 and AGE-3 showed a satura-
ble shape, suggesting the existence of upper limits of capacity
of incorporation.
Figure 3 shows typical pictures of AGE-2 and AGE-3
immunoreactivities at 2 hrs after the start of incubation with
AGEs. The incorporated immunoreactivities formed small
granule-like structures inside the cells, and some of the gran-
ules appeared to be present inside the nuclei (Figure 3(c)).
The 3D pictures suggested that the interaction of AGEs with
macrophages should include binding of AGEs to the cell sur-
face, incorporation into the cytoplasm and nuclear compart-
ments, and granule-like formation. Figure 3(a) shows the
distribution of AGE-2 in macrophages, with both cell-
membrane binding and cytoplasmic incorporation.
3.3. Eﬀects of Inhibitors of Endocytosis on Incorporation of
AGEs in Macrophages. To examine the mechanism of AGE
uptake into macrophages, cells were preincubated with cyto-
chalasin D, chlorpromazine, or FPS-ZM1 for 1 hr before the
start of AGE uptake. The presence of cytochalasin D, an
inhibitor of actin polymerization, blocked AGE-2 and
AGE-3 uptake in macrophages (Figure 4). The inhibition
by cytochalasin D was concentration-dependent and the
inhibitory eﬀect was signiﬁcant at a lower concentration of
5μg/ml. However, chlorpromazine, an inhibitor of clathrin-
dependent endocytosis, did not produce signiﬁcant eﬀects
on incorporation of AGEs up to the concentration of 20μg/
ml. As shown in Figure 4(c), the addition of FPS-ZM1, an
antagonist of RAGE, enhanced the incorporation of both
AGE-2 and AGE-3 in J774.1 cells in a concentration-
dependent manner. The enhancing eﬀects of FPS-ZM1
reached to maximal at 100nM. The quantitative data on ﬂuo-
rescence intensities of incorporated AGEs were presented
in Supplementary data 1.
3.4. Intracellular ROS Production during AGE Incorporation
into Macrophages. ROS production in macrophages stimu-
lated by AGEs was detected by DCF ﬂuorescence after uptake
of DCF-AM. Both AGE-2 and AGE-3 (100μg/ml) elicited
ROS production strongly in some populations of cells,
whereas the remainder of cells produced lower levels of
ROS 24hrs after the start of stimulation (Figure 5). In the
PBS and BSA control groups, there were no detectable levels
of ROS in the cells. As the bright-ﬁeld image shows, the total
numbers of cells were reduced in the groups exposed to AGE-
2 and AGE-3.
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3.5. Apoptosis of Macrophages after Uptake of AGE-2 and
AGE-3. We next checked the apoptosis-inducing eﬀects of
AGEs because intracellular ROS production may be associ-
ated with the induction of apoptosis.
Since the activation of caspase-3 is one of the markers of
apoptosis, we determined the activated form of caspase-3
(cleaved caspase-3) on Western blotting (Figure 6). Pro-
longed incubation with AGE-2 and AGE-3 at 20μg/ml for
24 hrs signiﬁcantly produced cleaved caspase-3 (Figure 6(a)).
The cleaved caspase-3 in theAGE-2 groupwas faint compared
with that in the AGE-3 group; however, the higher con-
centration of AGEs at 100μg/ml clearly showed that cleav-
age of caspase-3 was enhanced compared with the control
groups (Figure 6(b)).
As shown in Figure 7, incubation with AGE-2 and
AGE-3 induced the expression of phosphatidylserine (PS)
AGE-2 4°C 37°C
Triton X-100 (−) Triton X-100 (−) 
Triton X-100 (+) Triton X-100 (+) 
(a)
AGE-3 4°C 37°C
Triton X-100 (+) Triton X-100 (+) 
Triton X-100 (−) Triton X-100 (−) 
(b)
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Figure 1: Uptake of AGE-2 and AGE-3 in macrophages. J774.1 cells (106/ml, 100 μl) were plated in 96-well black/clear plates in the culture
medium without FBS. After adhesion was allowed for 1 hr, cells were incubated with BSA-AGE-2 or BSA-AGE-3 (20 μg/ml) for 2 hrs. The
incorporated BSA-AGE-2 or BSA-AGE-3 was detected by a speciﬁc polyclonal antibody made in our lab, and then a secondary antibody
(AlexaFluor 488-labeled goat anti-rabbit IgG (H+L)) was added to obtain ﬂuorescence. After ﬁxation, the cells were treated with TBS in
the presence or absence of 0.3% Triton X-100. Representative images are shown from four separate experiments. The ﬂuorescence
intensity was quantitated and the results are summarized in Figure 1(c). The results shown are means± SEMs of four separate
experiments. ∗∗p < 0 01 versus Triton X-100 (−).
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detected by annexin V binding on the cell surface 12 and
24 hrs after the start of incubation. The PS-positive cells
were precisely merged with the cells exhibiting high AGE
uptake (Figure 7).
These results showed that AGE-2 and AGE-3 induced
cell apoptosis and that the ability of AGE-3 to induce cell
apoptosis was stronger than that of AGE-2.
3.6. AGE-Induced 4-Hydroxynonenal (4-HNE) Production
and Activation of the NF-κB Pathway in Macrophages.
Finally, we determined the translocation of NF-κB p65
from the cytosolic to the nuclear compartment to evaluate
NF-κB activation. Figure 8(a) shows that most of NF-κB
immunoreactivity in the control cells was located in the
cytosolic compartment. However, the NF-κB p65 immuno-
reactivity was partially translocated into the nuclear com-
partment after stimulation with AGE-2 and AGE-3.
These immunocytochemical ﬁndings were consistent with
the results of Western blotting, which showed the nuclear
translocation of NF-κB p65 by stimulation with AGE-2
and AGE-3 (Figure 8(b)). The cells stimulated with
AGE-2 and AGE-3 also showed constant production of
4-HNE. This is consistent with ROS production during
AGE uptake.
4. Discussion
AGEs have been suggested to be involved in the pathogenesis
of many kinds of diseases, including diabetic complications,
atherosclerosis, nephropathy, and neuropathic pain [11,
12]. The nonenzymatic production of AGEs occurs in the
presence of higher concentrations of glucose in individuals
with diabetes. Moreover, oxidative stress probably facilitates
the formation of AGE adducts via the modiﬁcation of pro-
teins [13, 14]. There may be a diverse range of AGE subspe-
cies produced, among which AGE-2 and AGE-3 exhibit
strong toxic eﬀects on speciﬁc cells [15, 16]. Receptors for
advanced glycation end product (RAGE), SRA, LOX-1, and
CD36 are the candidate receptors believed to mediate the
various eﬀects of AGEs [17]. Soluble RAGE treatment can
cancel the eﬀect of AGEs and be used as a biomarker in
RAGE-dependent inﬂammation [18]. However, the mecha-
nisms by which AGEs are cleared from the extracellular envi-
ronment are inadequately understood. Therefore, we
examined the fundamental uptake mechanism of AGEs into
macrophages and its relevant eﬀects on cell viability to better
understand the fate of AGEs.
The present study clearly showed that J774.1 macro-
phages had the ability to incorporate AGE-2 and AGE-3 in
a temperature-dependent and saturable manner. Then, we
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Figure 2: Time course and concentration dependency of uptake of AGE-2 and AGE-3 and their subcellular localization in macrophages. (a)
The J774.1 macrophages were incubated with AGE-2 or AGE-3 (20 μg/ml) at 37°C for the indicated periods. The AGE-2 or AGE-3 in the cells
was detected by speciﬁc polyclonal antibodies as in Figure 1. Representative images from three separate experiments are shown. The
ﬂuorescence intensities were quantiﬁed with the results shown representing means± SEMs of three separate experiments. (b) The J774.1
macrophages were incubated with diﬀerent concentrations of AGE-2 or AGE-3 at 37°C for 1 hr. Representative images from three separate
experiments are shown. The ﬂuorescent intensities were quantiﬁed and results are shown as means± SEMs of three separate experiments.
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Figure 4: Eﬀects of endocytosis inhibitors or RAGE inhibitor on AGE-2 and AGE-3 uptake in J774.1 macrophages. The J774.1 macrophages
were preincubated with diﬀerent concentrations of cytochalasin D (a), chlorpromazine (b), and FPS-ZM1 (RAGE inhibitor) (c) at 37°C for
1 hr. Then, the cells were incubated with AGE-2 or AGE-3 (20 μg/ml) at 37°C for 30min. AGE-2 or AGE-3 was detected as shown in
Figure 1. Representative images from three separate experiments are shown.
AGE-2
(a)
AGE-3
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Figure 3: Three-dimensional images of J774.1 macrophages after AGE uptake. The J774.1 macrophages were incubated with 20μg/ml of
AGE-2 (a) or AGE-3 (b) at 37°C for 2 hrs. The immunoreactivities in the cells (green) were observed under confocal microscopy with
DAPI staining (blue). Serial sections in the z-axis are shown in the right-hand panels. Arrowheads in (c) indicate AGE-3-positive signals
in the nuclear compartment.
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examined the eﬀects of pretreatment with three inhibitors,
cytochalasin D, chlorpromazine, and FPS-ZM1 [19, 20], on
AGE-2 and AGE-3 incorporation in J774.1 cells. Cytochala-
sin D inhibits clathrin-independent endocytosis through
depolymerizing F-actin. Chlorpromazine translocates cha-
thrin and adaptor protein-2 from the cell surface to intracel-
lular endosomes and inhibits clathrin-mediated endocytosis.
The ﬁnding that cytochalasin D but not chlorpromazine
inhibited AGE-2/3 uptake into J774.1 cells strongly suggests
that AGE-2 and AGE-3 were taken up into macrophages
mainly through clathrin-independent endocytotic mecha-
nism but not through a clathrin-mediated mechanism.
FPS-ZM1 is a high-aﬃnity RAGE-speciﬁc blocker. In fact,
we demonstrated that FPS-ZM1 blocked the binding of
AGE-2 to sRAGE using surface plasmon resonance
(Supplementary data 2). Surprisingly, FPS-ZM1 enhanced
both AGE-2 and AGE-3 uptake into J774.1 cells. Since
AGE-2 and AGE-3 has been demonstrated to be high-
aﬃnity agonists for RAGE [21, 22], the eﬀects of FPS-
ZM1 on AGE-2/3 uptake strongly suggest the inhibitory
regulation by RAGE signaling on AGEs uptake mecha-
nism. Thus, the signaling through RAGE may inhibit the
clearance of AGE-2 and AGE-3, leading to the sustained
presence of extracellular AGEs.
The expression of phosphatidylserine on the surfaces of
macrophages increased in correlation with the amount of
AGE-2 or AGE-3 the macrophages incorporated suggesting
that apoptosis was induced after AGE incorporation.
Caspase-3 is also activated in apoptotic cells both by extrinsic
(death ligand) and intrinsic (mitochondrial) pathways;
hence, the suggestion of apoptosis was conﬁrmed by the
detection of cleaved caspase-3 in cells after prolonged incu-
bation with AGE-2 and AGE-3. It was shown in the present
study that the uptake of AGEs was associated with ROS pro-
duction and NF-κB activation. Because we clearly detected
the increased DCF ﬂuorescence and NF-κB translocation
into nuclei at an early time point after AGE stimulation, these
signaling pathways may be present upstream of caspase-3
activation, leading to cell apoptosis.
From the present study, it is postulated that macrophages
are among the cells that remove AGEs from the extracellular
environment. Previous studies suggested that AGEs might
exist both extracellularly and intracellularly. Injection of
aptamers produced against AGEs diminished the level of
AGEs deposited in the glomerulus in diabetic rats, even
though the exact mechanism was unclear [23]. In the present
study, AGE-2 and AGE-3 are soluble ligands but are not
bound to the extracellular matrix. Such soluble AGEs by
themselves maybe readily taken up into macrophages from
the extracellular environment.
Dense AGE immunoreactivities have been observed in
atherosclerotic plaques in experimental animals as well as
in human patients [24]. It is well known that these plaques
contain numerous moribund foam cells. Thus, it is likely that
AGEs bound to the cellular surface of foam cells induce oxi-
dation stress, thereby promoting inﬂammatory cytokines and
Bright eld Fluorescence Merge
AGE-2
AGE-3
PBS
BSA
Figure 5: AGE-2 or AGE-3 stimulated ROS production in J774.1
macrophages. The J774.1 macrophages were incubated with
100μg/ml of AGE-2, AGE-3 or BSA at 37°C for 24 hrs. ROS
production was detected by DCF ﬂuorescence after the hydrolysis
of DCF-AM inside the cells. Representative images from three
separate experiments are shown.
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Figure 6: Western blot analysis of caspase-3 activation in J774.1
macrophages after stimulation with AGE-2 and AGE-3. The J774.1
macrophages were incubated with 20μg/ml (a) and 100μg/ml (b) of
AGE-2, AGE-3, or BSA at 37°C for 12 and 24 hrs. Cleaved and
uncleaved caspase-3 was detected byWestern blotting.
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Figure 8: Double immunostaining of NF-κB p65 and 4-hydroxynonenal after stimulation with AGE-2 and AGE-3 in J774.1 macrophages.
The J774.1 macrophages were incubated with 100 μg/ml of AGE-2 or AGE-3 at 37°C for 12 hrs. (a) The cells were stained with anti-NF-κB
p65 and anti-4-hydroxynonenal together with DAPI. White arrowheads show the relative expression of NF-κB p65 in the nucleus after
incubation with AGE-2 and AGE-3. (b) After incubation, the J774.1 macrophages were collected, and nuclear and cytosolic fractions were
prepared for SDS-PAGE andNF-κB p65 detection byWestern blotting. Representative results from three independent experiments are shown.
PS staining 
0 hr Bright eld AGEs PS Merge
(a)
Bright eld AGEs PS Merge12 hr
PBS 
AGE-2
AGE-3
(b)
Figure 7: Expression of phosphatidylserine on the cell surface of J774.1 macrophages stimulated by AGE-2 and AGE-3. The J774.1
macrophages were incubated with 100 μg/ml of AGE-2 or AGE-3 at 37°C for 12 hrs. Phosphatidylserine (PS) on the cellular surface was
detected by anti-PS antibody. Merged pictures were obtained from AGE and PS staining. Arrowheads indicate double-staining cells.
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contributing to the expression of oxidized LDL (OxLDL)
receptors in human monocyte-derived macrophages [25].
Our study implies that AGE incorporation and accumulation
in macrophages in atherosclerotic plaques may be one of the
factors leading to cell death. Oxidized-LDL has been known
as an important factor that induces vascular endothelial cell
dysfunction and phenotype changes in monocytes inﬁltrated
into the intima. Since AGEs have been shown to induce gene
expression of two important OxLDL receptors—macrophage
scavenger receptor class A and CD36 [26, 27]—AGEs in ath-
erosclerotic plaques could facilitate phenotype changes in
macrophages in addition to the induction of apoptosis as
observed in the present study. The main form of oxidized-
LDL, which is taken up by LOX-1, was reported to be the
aldehyde-modiﬁed form, suggesting a close similarity to
AGEs [28, 29].
Another ﬁnding is the rapid production of 4-HNE
after incorporation of AGEs. AGE-induced ROS production
may induce 4-HNE productions in macrophages. Further
works are necessary to identify the molecular signals
involved in endocytosis of AGEs and the relationship
between the signal-producing system and AGE incorpora-
tion in macrophages.
5. Conclusions
In conclusion, the present study clearly showed that macro-
phages incorporated toxic AGEs, AGE-2 and AGE-3, by a
RAGE- or clathrin-independent endocytotic process. Uptake
of AGE-2 or AGE-3 into cells may be associated with ROS
production and NF-κB activation. Accumulation of AGE-2
and AGE-3 inside macrophage cells in turn appears to trigger
the activation of caspase-3, leading to apoptosis. These
processes might in part reﬂect the events that occur in ath-
erosclerotic plaques, especially with regard to foam cell death.
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